Evidence map›Paper›PMID 31722072›Full record

ArticleAnnals of surgical oncology2020

Lymph Node Positivity in One-Step Nucleic Acid Amplification is a Prognostic Factor for Postoperative Cancer Recurrence in Patients with Stage II Colorectal Cancer: A Prospective, Multicenter Study.

Michio Itabashi, Hirofumi Yamamoto, Naohiro Tomita, Masafumi Inomata, Kohei Murata, Shigeoki Hayashi, Yasuhiro Miyake, Seiji Igarashi, Takeshi Kato, Shingo Noura and 8 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Micrometastasis in lymph nodes of colorectal cancer.Annals of gastroenterological surgery · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Michio ItabashiInstitute of Gastroenterology, Tokyo Women's Medical University, Shinjuku, Japan.
Hirofumi YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Suita, Japan. hyamamoto@sahs.med.osaka-u.ac.jp.
Naohiro TomitaDivision of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
Masafumi InomataDepartment of Gastroenterological and Pediatric Surgery, Faculty of Medicine, Oita University, Oita, Japan.
Kohei MurataDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Shigeoki HayashiDepartment of Digestive Surgery, Nihon University Hospital, Chiyoda, Japan.
Yasuhiro MiyakeDepartment of Surgery, Osaka Minato Central Hospital, Osaka, Japan.
Seiji IgarashiDivision of Pathology, Tsuboi Cancer Center Hospital, Koriyama, Japan.
Takeshi KatoDepartment of Colorectal Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Shingo NouraDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Tomohisa FuruhataDivision of Gastroenterological and General Surgery, St. Marianna University Toyoko Hospital, Kawasaki, Japan.
Heita OzawaDepartment of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan.
Ichiro TakemasaDepartment of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan.
Masayoshi YasuiDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Hiroshi TakeyamaDepartment of Surgery, Minoh City Hospital, Minoh, Japan.
Shu OkamuraDepartment of Surgery, Suita Municipal Hospital, Suita, Japan.
Yuko OhnoDepartment of Mathematical Health Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Nariaki MatsuuraOsaka International Cancer Institute, Osaka, Japan.
Osaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka University · JPHyogo Medical University · JPKansai Rosai Hospital · JPMinoh City Hospital · JPNihon University · JPOita University · JPOsaka Hospital · JPOsaka National Hospital · JPOsaka Rosai Hospital · JPSapporo Medical University · JPSt. Marianna University School of Medicine · JPSuita Municipal Hospital · JPTochigi Cancer Center · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor colorectal cancer (CRC) patients, the standard histological lymph node (LN) evaluation has low sensitivity. Our previously developed one-step nucleic acid amplification (OSNA™) assay measures cytokeratin 19 gene expression in whole LNs. We recently showed that 17.6% of pN0 stage II CRC patients were OSNA positive, suggesting a correlation between OSNA results and disease recurrence. This multicenter, prospective study investigateed the prognostic value of the OSNA assay for pStage II CRC patients.

methodsWe examined 204 CRC patients who were preoperatively diagnosed as cN0 and cN1 and surgically treated at 11 medical institutions across Japan. Nine patients were excluded, and 195 patients (Stage I: n = 50, Stage II: n = 70, Stage III: n = 75) were examined. All LNs, harvested from patients, were examined histopathologically using one-slice hematoxylin-eosin staining. Furthermore, half of the LNs was examined by the OSNA assay. Patients were classified according to the UICC staging criteria and OSNA results, and the 3-year, disease-free survival (DFS) of each cohort was analyzed.

resultsAverage 21.2 LNs/patient were subject to pathological examination. Approximately half of all harvested LNs (average, 9.4 LNs/patient) were suitable for the OSNA assay. Significantly lower 3-year DFS rates were observed in pStage (pathological Stage) II OSNA-positive patients than in OSNA-negative patients (p = 0.005). Among all assessed clinical and pathological parameters, only the OSNA result significantly affected 3-year DFS rates in pStage II CRC patients (p = 0.027).

conclusionsThis study shows that OSNA positivity is a risk factor for recurrence of the patients with pStage II CRC.

Indexed as

Nucleic Acid Amplification TechniquesAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalFemaleHumansJapanKeratin-19Lymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalBiomarkers, TumorKeratin-19RNA, Messenger

Identifiers

PMID31722072
PMCPMC7060165
OpenAlexW2988777602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.